NCT02133105 (ELDOR) is a Phase 3 clinical trial of Levosimendan in Cardiorenal Syndrome, sponsored by Göteborg University.

Who is sponsoring NCT02133105?

NCT02133105 is sponsored by Göteborg University.

What drugs are being tested in NCT02133105?

Interventions in NCT02133105: Levosimendan, Dobutamine.

What condition does NCT02133105 study?

NCT02133105 studies Cardiorenal Syndrome.

Is NCT02133105 still recruiting?

NCT02133105 is currently completed. Last updated 24 February 2020.

Last reviewed 2020-02-24 · How we verify

NCT02133105: ELDOR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy of Intravenous Levosimendan Compared With Dobutamine on Renal Hemodynamics and Function in Chronic Heart Failure

Completed Phase 3 Last updated 24 February 2020

What this trial tests

Phase 3 trial testing Levosimendan in Cardiorenal Syndrome in 33 participants. Completed in 1 May 2017.

Timeline

1 April 2014

Primary endpoint
1 May 2017

1 May 2017

Quick facts

Lead sponsor	Göteborg University
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	33
Start date	1 April 2014
Primary completion	1 May 2017
Estimated completion	1 May 2017
Sites	1 location across Sweden

Drugs / interventions tested

Levosimendan (LEVOSIMENDAN) — full drug profile →
Dobutamine (DOBUTAMINE) — full drug profile →

Conditions studied

Cardiorenal Syndrome — all drugs for Cardiorenal Syndrome →

Sponsor

Göteborg University

Who can join

18 and older, any sex, with Cardiorenal Syndrome. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Change in renal blood flow
Time frame: 75 min minus baseline
Para-aminohippuric acid (PAH) infusion clearance
Change in glomerular filtration rate
Time frame: 75 min minus baseline
Chrome-ethylenediaminetetraacetic acid (EDTA) infusion clearance

Sponsor's own description

Although inotropes have a favorable effect on central hemodynamics in patients with heart failure, their effect on renal hemodynamics is incompletely defined. The purpose of this study is to evaluate the efficacy of a 75 min intravenous infusion of levosimendan compared to a 75 min infusion of dobutamine on renal hemodynamics and function in patients with chronic heart failure and signs of cardiorenal syndrome. The investigators hypothesis is that patients treated with levosimendan will show greater increases in renal blood flow and glomerular filtration rate (GFR) than those treated with dobutamine.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Differential Effects of Levosimendan and Dobutamine on Glomerular Filtration Rate in Patients With Heart Failure and Renal Impairment:A Randomized Double-Blind Controlled Trial.
Lannemyr L, Ricksten SE, Rundqvist B, Andersson B, et al · · 2018 · cited 46× · PMID 30369310 · DOI 10.1161/jaha.117.008455
Acute kidney injury: emerging pharmacotherapies in current clinical trials.
Benoit SW, Devarajan P. · · 2018 · cited 33× · PMID 28601936 · DOI 10.1007/s00467-017-3695-3
Differential effects of inotropes and inodilators on renal function in acute cardiac care.
Zima E, Farmakis D, Pollesello P, Parissis JT. · · 2020 · cited 12× · PMID 32431569 · DOI 10.1093/eurheartj/suaa091
Cardiorenal Syndrome Type 1: Renal Dysfunction in Acute Decompensated Heart Failure.
Prins KW, Thenappan T, Markowitz JS, Pritzker MR. · · 2015 · cited 8× · PMID 27158218

Verify or expand the search:

Other trials of Levosimendan

Trials testing the same drug.

NCT07262723 — Levosimendan in Acute Decompensated Heart Failure · Phase 2, PHASE3 · not yet recruiting
NCT05664191 — Levosimendan as Treatment of Aneurysmal SubArachnoid Haemorrhage · Phase 2 · recruiting
NCT06021587 — Interest of Levosimendan Preconditioning for Cardiac Surgery Under CEC in Heart Failure Patients With Impaired Ejection · unknown
NCT05730907 — Efficacy and Clinical Outcomes of Levosimendan in E-CPR · unknown
NCT05233202 — Levosimendan Versus Placebo Before Tricuspid Valve Surgery in Patients With Right Ventricular Dysfunction · Phase 3 · unknown

Other recruiting trials for Cardiorenal Syndrome

Currently open trials in the same condition.

NCT07167368 — Exercise Rehabilitation for Cardiorenal Syndrome in HFrEF Patients · NA · recruiting
NCT06714409 — Venous Ultrasound Guided Organ Decongestion in Patients Hospitalized with Acute Decompensated Heart Failure · NA · recruiting

Other Göteborg University trials

Trials by the same sponsor.

NCT07260604 — HIFEM for Incontinence After Menopause High-Intensity Focused Electromagnetic (HIFEM) · NA · not yet recruiting
NCT07401420 — Life Sustaining Treatments in Critically Ill Children · not yet recruiting
NCT07213245 — Metabolic Effects of Short-term Ultra-processed Food Intake (MEST-UPF) · NA · recruiting
NCT07178405 — Effects of Meal Characteristics on Appetite · NA · completed
NCT07172841 — Non-invasive Diagnostics of Shunt Obstruction in Adult Hydrocephalus · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02133105 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Göteborg University
Last refreshed: 24 February 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02133105.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing